Loomis Sayles & Co. L P Has $41.68 Million Stock Holdings in CRISPR Therapeutics AG $CRSP

Loomis Sayles & Co. L P trimmed its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 5.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 856,887 shares of the company’s stock after selling 52,905 shares during the quarter. Loomis Sayles & Co. L P owned about 0.94% of CRISPR Therapeutics worth $41,679,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of CRSP. IVC Wealth Advisors LLC acquired a new stake in shares of CRISPR Therapeutics during the second quarter worth $225,000. Koss Olinger Consulting LLC grew its stake in shares of CRISPR Therapeutics by 29.8% in the second quarter. Koss Olinger Consulting LLC now owns 42,197 shares of the company’s stock valued at $2,052,000 after acquiring an additional 9,685 shares in the last quarter. Vanguard Group Inc. increased its position in CRISPR Therapeutics by 1.9% during the first quarter. Vanguard Group Inc. now owns 1,769,709 shares of the company’s stock worth $60,223,000 after acquiring an additional 33,711 shares during the period. Slow Capital Inc. raised its stake in CRISPR Therapeutics by 15.6% in the 2nd quarter. Slow Capital Inc. now owns 75,396 shares of the company’s stock worth $3,667,000 after purchasing an additional 10,152 shares in the last quarter. Finally, Intellectus Partners LLC acquired a new stake in CRISPR Therapeutics in the 2nd quarter worth about $284,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Wedbush decreased their target price on shares of CRISPR Therapeutics from $13.00 to $9.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 5th. Robert W. Baird cut their price target on CRISPR Therapeutics from $52.00 to $44.00 and set a “neutral” rating for the company in a research note on Tuesday, November 11th. HC Wainwright restated a “buy” rating and set a $80.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, September 23rd. Royal Bank Of Canada lifted their price objective on CRISPR Therapeutics from $42.00 to $50.00 and gave the company a “sector perform” rating in a report on Tuesday, November 11th. Finally, Zacks Research upgraded CRISPR Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 26th. Eleven research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $67.42.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP opened at $53.63 on Friday. CRISPR Therapeutics AG has a 1 year low of $30.04 and a 1 year high of $78.48. The stock has a market capitalization of $5.11 billion, a price-to-earnings ratio of -9.59 and a beta of 1.89. The company’s 50 day simple moving average is $61.92 and its 200 day simple moving average is $54.74.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, November 10th. The company reported ($1.17) earnings per share for the quarter, topping the consensus estimate of ($1.32) by $0.15. CRISPR Therapeutics had a negative return on equity of 21.23% and a negative net margin of 1,273.70%.The firm had revenue of $0.89 million during the quarter, compared to analysts’ expectations of $8.74 million. As a group, analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In related news, General Counsel James R. Kasinger sold 1,076 shares of the firm’s stock in a transaction dated Tuesday, October 14th. The stock was sold at an average price of $66.60, for a total value of $71,661.60. Following the sale, the general counsel directly owned 83,402 shares of the company’s stock, valued at $5,554,573.20. This trade represents a 1.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Samarth Kulkarni sold 50,895 shares of the business’s stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $67.91, for a total value of $3,456,279.45. Following the transaction, the chief executive officer directly owned 254,201 shares of the company’s stock, valued at approximately $17,262,789.91. The trade was a 16.68% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 56,213 shares of company stock valued at $3,810,458. 4.30% of the stock is owned by corporate insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.